Although the β-amyloid hypothesis for AD pathogenesis has paramount supporting evidence, including cellular and animal toxicity of Aβ aggregates, the loss-of-function mutations in FAD-linked APP and γ-secretase remain difficult to be explained and could have important implications in drug discovery for AD. This evidence concerns the gene APP and Alzheimer disease.